These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45 related articles for article (PubMed ID: 33544355)
1. Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study. Pfohl M; Seufert J; Borck A; Bramlage P; Siegmund T Diabetes Ther; 2021 Mar; 12(3):733-747. PubMed ID: 33544355 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study. Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356 [TBL] [Abstract][Full Text] [Related]
3. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402 [TBL] [Abstract][Full Text] [Related]
4. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Davies M; Evans R; Storms F; Gomis R; Khunti K Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063 [TBL] [Abstract][Full Text] [Related]
5. Short Term Efficacy and Safety of Insulin Glargine in Type 2 Diabetes Inadequately Controlled with Single or Two Oral Agents: A Prospective, Open Label Study. Aggarwal A; Wadhwa R J Clin Diagn Res; 2017 Jul; 11(7):OC21-OC24. PubMed ID: 28892956 [TBL] [Abstract][Full Text] [Related]
6. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study. Jin Y; Sun X; Zhao X; Zhu T Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related]
8. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Furler J; O'Neal D; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Doyle R; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins A; Lake AJ; Januszewski AS; Catchpool M; Liew D; Clarke P; Best J Lancet Diabetes Endocrinol; 2020 Jan; 8(1):17-26. PubMed ID: 31862147 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus. Gómez-Huelgas R; Sabán-Ruiz J; García-Román FJ; Quintela-Fernández N; Seguí-Ripoll JM; Bonilla-Hernández MV; Romero-Meliá G Rev Clin Esp (Barc); 2017 May; 217(4):201-206. PubMed ID: 28314656 [TBL] [Abstract][Full Text] [Related]
10. Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes. Konstantinova M; Loizeau V; Pilorget V; Cali A; Danne T Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):523-7. PubMed ID: 25054310 [TBL] [Abstract][Full Text] [Related]
11. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective]. Jermendy G; Kovács G Orv Hetil; 2018 Dec; 159(50):2122-2128. PubMed ID: 30545262 [TBL] [Abstract][Full Text] [Related]
13. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857 [TBL] [Abstract][Full Text] [Related]
14. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P; Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116 [TBL] [Abstract][Full Text] [Related]
15. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER. Takahara M; Mita T; Katakami N; Wada F; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H; Diabetes Ther; 2022 Feb; 13(2):251-264. PubMed ID: 34962628 [TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
17. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification. Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023 [TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study. Temelkova N; Vladeva S; Delchev A; Ivanova K; Gerasimova-Zheleva Y; Kuneva T; Pehlivanova V; Popivanov P Diabetes Ther; 2019 Jun; 10(3):981-993. PubMed ID: 30919317 [TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C; BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112 [TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). REPOSE Study Group BMJ; 2017 Mar; 356():j1285. PubMed ID: 28360027 [No Abstract] [Full Text] [Related] [Next] [New Search]